03803nam 2200637Ia 450 991078118840332120230725044903.00-309-15135-X1-282-50135-697866125013570-309-14576-7(CKB)2550000000010479(EBL)3378590(SSID)ssj0000425571(PQKBManifestationID)11285363(PQKBTitleCode)TC0000425571(PQKBWorkID)10367984(PQKB)11669130(MiAaPQ)EBC3378590(Au-PeEL)EBL3378590(CaPaEBR)ebr10370368(CaONFJC)MIL250135(OCoLC)923281442(EXLCZ)99255000000001047920100301d2010 uy 0engurcn|||||||||txtccrPolicy issues in the development of personalized medicine in oncology[electronic resource] workshop summary /Margie Patlak and Laura Levit, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Institute of Medicine of the National AcademiesWashington, D.C. National Academies Pressc20101 online resource (95 p.)" ... the National Cancer Policy Forum held a workshop, "Policy Issues in the Development of Personalized Medicine in Oncology," in Washington, DC, on June 8 and 9, 2009."--P. 1.0-309-14575-9 Includes bibliographical references (p. 65-70).""Front Matter""; ""Reviewers""; ""Contents""; ""Introduction""; ""Personalized Cancer Medicine Technology""; ""Regulation of Predictive Tests""; ""Reimbursement""; ""Summary""; ""References""; ""Acronyms""; ""Glossary""; ""Appendix A: Workshop Agenda""; ""Appendix B: Workshop Speakers and Moderators"""One of the challenges in treating cancer is the disease's complexity and variation among patients. Cancer manifests differently in each patient, so treatments that are effective in one patient may not be effective in another. As cancer care becomes more personalized, subpopulations of individuals will be given preventive or therapeutic interventions based on their susceptibility to a particular disease or their predicted response to a specific treatment. However, before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of technological, regulatory, and reimbursement issues. To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009. Experts provided presentations on the current state of personalized medicine technology, as well as issues in the validation of, regulation of, and reimbursement for the predictive tests that underpin personalized medicine. Participants discussed the obstacles and possible solutions to further developing and using personalized medicine technologies. This document summarizes the workshop."--Publisher's description.CancerTreatmentUnited StatesMedical careUnited StatesMedical policyUnited StatesCancerTreatmentMedical careMedical policy616.994Levit Laura A1510137Patlak Margie1476477Institute of Medicine (U.S.).Board on Health Care Services.National Cancer Policy Forum (U.S.)MiAaPQMiAaPQMiAaPQBOOK9910781188403321Policy issues in the development of personalized medicine in oncology3742458UNINA